Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Barrett Esophagus 2Adenocarcinoma Of Esophagus 2Squamous Cell Carcinoma of Head and Neck 1Precancerous Conditions 1Lymphoma, Primary Effusion 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Laryngeal Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colorectal Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1

Interventions

Rituximab 4Vincristine 3Prednisone 3Filgrastim 3Etoposide 3Doxorubicin 3Cyclophosphamide 3prednylidene 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1liposomal doxorubicin 1ibrutinib 1etoposide phosphate 1deltacortene 1Ultrasonography 1Lenalidomide 1Granulocyte Colony-Stimulating Factor 1Endoscopy 1Electrocardiography 1Echocardiography 1CT-P10 1Bronchoscopy 1Amplified Fragment Length Polymorphism Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, AIDS-Related × Endoscopy × Clear all
NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
17 enrolled 21 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡